# MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)

> **NCT01085331** · PHASE1,PHASE2 · TERMINATED · sponsor: **EMD Serono** · enrollment: 16 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Pimasertib
- **DRUG:** Placebo
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT01085331
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Conduct the randomized Phase 2 part not recommended due to the achieved MTD for pimasertib (45mg/day) in combination with FOLFIRI
- **Last updated:** 2016-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01085331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01085331, "MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01085331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*